AI and Automation Dominated SLAS2026

- The cell and gene therapy CDMO market is projected to grow from USD 4.31 billion in 2026 to USD 9.08 billion by 2031, reflecting a compound annual growth rate of 16.08%. This expansion is largely driven by the increasing demand for specialized manufacturing capabilities for complex treatments like CAR-T therapies and viral vectors. Key players in this market include Catalent, Lonza, and Wuxi Advanced Therapies. - A significant challenge in viral vector production is the reliance on transient transfection of HEK293 cells for each new batch, which creates a high demand and cost for plasmid manufacturing. The lack of stable, high-producing cell lines, similar to the CHO cells used for monoclonal antibodies, complicates process scalability and consistency. - Digital twins are being developed to optimize viral vector manufacturing by creating virtual models of the bioprocess that can predict outcomes and support closed-loop process control. Companies like Généthon and Thalès are collaborating to use AI to model bioprocessing steps to improve yields. These models integrate real-time data from process analytical technology (PAT) to enhance predictive accuracy for critical parameters like VLP titer and impurity levels. - Electronic Batch Records (EBRs) are replacing paper-based systems to improve data integrity and streamline compliance in GMP environments. Vendors like Sapio Sciences and Tulip Interfaces offer EBR solutions that integrate with LIMS and MES to automate data capture from equipment, enforce procedural workflows, and reduce batch review times by enabling review-by-exception. - A major hurdle in cell and gene therapy manufacturing is the lack of data standardization, which complicates process analytics, comparability studies, and regulatory filings. This is particularly challenging for autologous therapies where an increase in production volume directly correlates with a massive increase in data collection and analysis for each individual batch. - The biotech funding environment is showing signs of recovery, with a surge in public small and mid-cap biotech stocks in the latter half of 2025 expected to open up the IPO market in 2026. This could lead to increased private funding in the later quarters of 2026, though investors are expected to remain selective, favoring companies with strong clinical data. - In 2025, a notable shift in biotech funding strategies emerged, with 41% of companies planning to seek additional funding for R&D, a significant increase from 14% in 2023. The primary sources for this funding are large pharma partnerships, venture capital, and government grants. - To mitigate geopolitical and supply chain risks, a trend toward localizing manufacturing capacity in the U.S. and Europe is expected to continue through 2026. This is driving innovators with late-stage and commercial molecules to reserve capacity with regional CDMOs to ensure supply chain security.